Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity

British Journal of Cancer volume 124, pages 1035–1036 (2021)Cite this article

Subjects

A Correction to this article was published on 10 March 2021

This article has been updated

Summary

Phosphatases of regenerating liver (PRL1–3) are among the most oncogenic protein phosphatases but their mechanism of action is poorly understood. Multiple substrates have been proposed as well as a non-catalytic function regulating magnesium transport. Our recent identification of a catalytically inactive PRL mutant that retains oncogenicity in a mouse model promises to resolve the question of whether PRLs act as phosphatases or pseudo-phosphatases in different cancer models.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: PRL3 acts as a pseudo-phosphatase.

Change history

References

  1. Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S. & Taub, R. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 14, 3752–3762 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., St Croix, B. et al. A phosphatase associated with metastasis of colorectal cancer. Science 294, 1343–1346 (2001).

    Article  CAS  Google Scholar 

  3. Funato, Y., Yamazaki, D., Mizukami, S., Du, L., Kikuchi, K. & Miki, H. Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression. J. Clin. Investig. 124, 5398–5410 (2014).

    Article  Google Scholar 

  4. Hardy, S., Uetani, N., Wong, N., Kostantin, E., Labbe, D. P., Begin, L. R. et al. The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis. Oncogene 34, 986–995 (2015).

    Article  CAS  Google Scholar 

  5. Gulerez, I., Funato, Y., Wu, H., Yang, M., Kozlov, G., Miki, H. et al. Phosphocysteine in the PRL-CNNM pathway mediates magnesium homeostasis. EMBO Rep. 17, 1890–1900 (2016).

    Article  CAS  Google Scholar 

  6. Kozlov, G., Cheng, J., Ziomek, E., Banville, D., Gehring, K. & Ekiel, I. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J. Biol. Chem. 279, 11882–11889 (2004).

    Article  CAS  Google Scholar 

  7. Funato, Y. & Miki, H. Reversible oxidation of PRL family protein-tyrosine phosphatases. Methods 65, 184–189 (2014).

    Article  CAS  Google Scholar 

  8. Zhang, H., Kozlov, G., Li, X., Wu, H., Gulerez, I. & Gehring, K. PRL3 phosphatase active site is required for binding the putative magnesium transporter CNNM3. Sci. Rep. 7, 48 (2017).

    Article  Google Scholar 

  9. Gimenez-Mascarell, P., Oyenarte, I., Hardy, S., Breiderhoff, T., Stuiver, M., Kostantin, E. et al. Structural basis of the oncogenic interaction of phosphatase PRL-1 with the magnesium transporter CNNM2. J. Biol. Chem. 292, 786–801 (2017).

    Article  CAS  Google Scholar 

  10. Kozlov, G., Funato, Y., Chen, Y. S., Zhang, Z., Illes, K., Miki, H. et al. PRL3 pseudophosphatase activity is necessary and sufficient to promote metastatic growth. J. Biol. Chem. 295, 11682–11692 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Centre de Recherche en Biologie Structurale, McGill University, Montreal, QC, Canada

    Kalle Gehring

  2. Department of Cellular Regulation, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan

    Hiroaki Miki

Authors
  1. Kalle Gehring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.G. and H.M. contributed to the writing, revision, and approval of this manuscript.

Corresponding author

Correspondence to Kalle Gehring.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Data availability

Not applicable.

Competing interests

The authors declare no competing interests.

Funding information

This work was supported by the Natural Sciences and Engineering Research Council of Canada.

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: There was a typo in the text.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gehring, K., Miki, H. Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity. Br J Cancer 124, 1035–1036 (2021). https://doi.org/10.1038/s41416-020-01194-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-020-01194-9

Search

Advanced search

Quick links